Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Mouse Explants Generated from Patients' Circulating Tumor Cells Pave Way for Directed Personalized Chemotherapy

By BiotechDaily International staff writers
Posted on 19 Jun 2014
Image: Histopathologic image of small-cell lung cancer (Photo courtesy of Wikimedia Commons).
Image: Histopathologic image of small-cell lung cancer (Photo courtesy of Wikimedia Commons).
Cancer researchers have isolated circulating tumor cells (CTCs) from patients with small-cell lung cancer (SCLC) and implanted them into immunocompromised mice to use as a model system for developing better treatments for the disease.

SCLC is an aggressive neuroendocrine tumor with early dissemination and poor prognosis that accounts for 15%–20% of lung cancer cases and approximately 200,000 deaths in the United Kingdom each year. Most cases are inoperable, and biopsies to investigate SCLC biology are rarely obtainable. A more promising approach for studying SCLC is by collecting "liquid biopsy" specimens—CTCs, which are prevalent in the blood of SCLC patients.

Investigators at the University of Manchester (United Kingdom) reported in June 1, 2014, online edition of the journal Nature Medicine that CTCs from SCLC patients who either responded to chemotherapy or failed to respond to chemotherapy developed into tumors in immunocompromised mice. The resultant CTC-derived explants (CDXs) mirrored the donor patient's response to platinum and etoposide chemotherapy. Genomic analysis of isolated CTCs revealed considerable similarity to the corresponding CDX.

Senior author Dr. Caroline Dive, professor of pharmacology and pharmacy at the University of Manchester, said, “Access to sufficient tumor tissue is a major barrier to fully understanding the biology of SCLC. This liquid biopsy is straightforward and not invasive so can be easily repeated and will allow us to study the genetics of each lung cancer patient’s individual tumor. It also means that we may have a feasible way of monitoring patient response to therapy, hopefully allowing us to personalize and tailor individual treatment plans to each patient. We can use these models to help us understand why so many SCLC patients acquire resistance to chemotherapy and to search for and test potential new targeted treatments.”

Related Links:

University of Manchester



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.